Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Patient's own kidney cells slow kidney disease?

NCT ID NCT05918523

Disease control Sponsor: Prokidney Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This study follows people with chronic kidney disease who previously received an experimental treatment called REACT, which uses a patient's own kidney cells to try to repair damaged kidneys. Researchers will track participants for years to see if the therapy causes any delayed side effects and how well their kidneys hold up over time. The goal is to understand whether this cell therapy can safely help people with diabetic kidney disease avoid or delay dialysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Renal Autologous Cell Therapy (REACT), an experimental cell therapy made from a person's own kidney cells, injected into the kidney
What this could lead to
If REACT proves safe and effective over the long term, it could offer a new way to slow chronic kidney disease and delay the need for dialysis.
What could go wrong
This is a follow-up study, not a new treatment test, and it involves a small number of participants. The therapy may not show lasting benefits, and there are risks of side effects from the injection or biopsy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with CKD

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol. Exclusion Criteria: * The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney diseases Diabetic kidney disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Boise Kidney & Hypertension Institute

    RECRUITING

    Meridian, Idaho, 83642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.